Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive ALL

Choosing Wisely in RT oncology

Management of HER2 positive metastatic breast cancer treatment algorithm

Spindle cell lesions of the breast

The role of lymph nodes in stage 3 lung cancer

Updates on HER2-low breast cancer

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of MIBC patients

Stereotactic body radiotherapy compared with surgery for localised prostate cancer

New era of early cancer detection blood tests on the horizon

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Olaparib continues to show positive results in advanced ovarian cancer - 7 year data

Metastatic breast cancer endpoints for survival: rwPFS and TTNT

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/met...

Treatment algorithm in systemic management of advanced prostate cancer

Low-dose nivolumab leads to improved overall survival for head and neck cancer patients

R-CODOX-M/R-IVAC versus dose-adjusted-EPOCH-R in patients with newly diagnosed high-risk lymphoma

Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive ALL

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

LUMINA results: Women with low levels of the Ki67 biomarker can avoid outcomes related to RT

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts

ASCO 2022: Breast cancer highlights

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes...

Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma